Close
0
You have no items in your order cart.
Search
Filters

Dog & Cat Vaccines

View as Grid List
Sort by
Display per page

Bronchishield - 10

114611
For active immunisation of dogs from 8 weeks of age to reduce coughing caused by Bordetella bronchiseptica. By intranasal administration. Active ingredient: Bordetella bronchiseptica

Canixin DHPPi/L & Solvent - 1ml x10

143694
Target species: Dog Indications for use For active immunisation of dogs from 8 weeks of age to: -prevent mortality and clinical signs of canine distemper and infectious canine hepatitis caused by canine adenovirus type 1; -prevent mortality and clinical signs and reduce excretion caused by canine parvovirus in a challenge study performed with a CPV2b strain; -reduce respiratory clinical signs caused by canine parainfluenza virus; -prevent mortality and reduce infection, clinical signs, kidney colonisation, renal lesions and urine shedding of L. canicola and L. icterohaemorrhagiae; The onset of immunity has been demonstrated from 3 weeks after the primary vaccination for CDV and CPV, 4 weeks for CAV-1 and CPIV, 5 weeks for L. canicola and 2 weeks for L. icterohaemorrhagiae. The duration of immunity lasts for one year after the primary vaccination for all components. For CAV-2 and CPV components, the duration of immunity was demonstrated by

Eurican Dhppi - 1ml x10

124090
A combined live freeze-dried vaccine against canine distemper, infectious canine hepatitis, canine parvovirus and canine parainfluenza virus type 2. Each 1-ml dose of vaccine contains attenuated canine distemper virus, at least 104.0 CCID50, attenuated canine adenovirus (CAV2), at least 102.5 CCID50, attenuated canine parvovirus, at least 104.9 CCID50, attenuated canine parainfluenza type 2 virus, at least 104.7 CCID50 Uses Dogs and puppies from 8 weeks of age: Active immunization against distemper to reduce mortality and clinical signs; against infectious canine hepatitis to prevent clinical signs; against parvovirus to prevent clinical signs and reduce mortality and viral excretion; and against parainfluenza type 2 infections to reduce clinical signs and viral excretion. Onset of immunity: 2 weeks after completion of the primary vaccination course. Duration of immunity: 1 year. Dosage and administration Reconstitute the vaccine with Eurican L using a clean sterile syringe. Use the vaccine immediately after reconstitution of the freeze-dried pellet. Apply usual aseptic procedures. Use sterile and/or disinfectant-free equipment for injection purposes. Administer by subcutaneous injection. The following vaccination schedule is recommended: Primary vaccination: 1st injection: from 8th week of age. 2nd injection: 3 to 5 weeks later, from 12th week of age. Revaccination: Booster injections should be given annually thereafter.

Eurican Herpes - 1ml

110061
Active immunisation of bitches to prevent mortality, clinical signs and lesions in puppies resulting from canine herpes virus infections acquired in the first few days of life.

Eurican L - 1ml x10

124130
Active immunisation against Leptospira canicola and Leptospira icterohaemorrhagiae to prevent mortality and to reduce clinical symptoms of Leptospira infections caused by these agents. For dogs and puppies from 8 weeks of age. VPA 10857/055/001.

Eurican L Multi - 1ml x10

141334
Indications for use Active immunisation of dogs to: -prevent mortality, clinical signs, infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae -prevent mortality* and clinical signs, reduce infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Canicola serovar Canicola. -prevent mortality*, and reduce clinical signs, infection, bacterial excretion renal carriage and renal lesions caused by Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa. - prevent mortality, clinical signs, renal infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Copenhageni.** Onset of immunity: 2 weeks after the second injection of the primary vaccination course for all strains Duration of immunity: at least one year after the second injection of the primary vaccination course for all strains * For Leptospira Canicola and Grippotyphosa, no mortality occurred during challenge experiment for duration of immunity. ** For Leptospira Copenhageni the duration of immunity was not establishedIndications for use Active immunisation of dogs to: -prevent mortality, clinical signs, infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae -prevent mortality* and clinical signs, reduce infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Canicola serovar Canicola. -prevent mortality*, and reduce clinical signs, infection, bacterial excretion renal carriage and renal lesions caused by Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa. - prevent mortality, clinical signs, renal infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira interrogans serogroup Icterohaemorrhagiae serovar Copenhageni.** Onset of immunity: 2 weeks after the second injection of the primary vaccination course for all strains Duration of immunity: at least one year after the second injection of the primary vaccination course for all strains * For Leptospira Canicola and Grippotyphosa, no mortality occurred during challenge experiment for duration of immunity. ** For Leptospira Copenhageni the duration of immunity was not established

Eurican/Purevax Syringe

148164
For use with Eurican & Purevax vaccines

Fevaxyn Pentofel IE/SE/FI - 1ml x10

114661
For active immunisation of healthy cats of 9 weeks of age or older against Feline panleukopenia, Feline leukaemia viruses and against respiratory disease caused by Feline rhinotracheitis virus, Feline caliciviris and Chlamydophila felis. Single subcutaneous dose. .

Leucofeligen FeLV/RCP - 1ml x10

137264
For active immunisation of cats from eight weeks of age against: -feline calicivirosis to reduce clinical signs. -feline viral rhinotracheitis to reduce clinical signs and viral excretion. -feline panleucopaenia to prevent leucopenia and to reduce clinical signs. -feline leukaemia to prevent persistent viraemia and clinical signs of the related disease. -Onset of immunity: 3 weeks after the primary vaccination for the panleucopaenia and leukaemia components, and 4 weeks after the primary vaccination for the calicivirus and rhinotracheitis virus components. -After the primary vaccination course, the duration of immunity lasts for one year for all components. -Following a first booster vaccination one year after the primary vaccination course, a duration of immunity of 3 years has been demonstrated for the leukaemia component. Subcutaneous use. Reconstitute one dose of lyophilisate with one dose of solvent, shake gently and administer immediately. Administer subcutaneously one dose of the veterinary medicinal product according to the following regimen of vaccination. Primary vaccination: -first injection in kittens from 8 weeks of age -second injection 3 or 4 weeks later Maternally derived antibodies can negatively influence the immune response to vaccination. In such cases where maternally derived antibodies are expected, a third injection may be appropriate from 15 weeks of age. Revaccination: Following a first booster vaccination one year after the primary vaccination course, subsequent vaccinations can be performed at intervals of three years for the leukaemia component. In this case, since annual revaccination is required for calcivirus, rhinotracheitis virus and panleucopenia virus components, a single dose of Feligen RCP can be used annually. This vaccine can be used as a booster for kittens or cats previously vaccinated with FELIGEN RCP and LEUCOGEN separately.

Leucofeligen FeLV/RCP - 1ml x50

137274
For active immunisation of cats from eight weeks of age against: -feline calicivirosis to reduce clinical signs. -feline viral rhinotracheitis to reduce clinical signs and viral excretion. -feline panleucopaenia to prevent leucopenia and to reduce clinical signs. -feline leukaemia to prevent persistent viraemia and clinical signs of the related disease. -Onset of immunity: 3 weeks after the primary vaccination for the panleucopaenia and leukaemia components, and 4 weeks after the primary vaccination for the calicivirus and rhinotracheitis virus components. -After the primary vaccination course, the duration of immunity lasts for one year for all components. -Following a first booster vaccination one year after the primary vaccination course, a duration of immunity of 3 years has been demonstrated for the leukaemia component. Subcutaneous use. Reconstitute one dose of lyophilisate with one dose of solvent, shake gently and administer immediately. Administer subcutaneously one dose of the veterinary medicinal product according to the following regimen of vaccination. Primary vaccination: -first injection in kittens from 8 weeks of age -second injection 3 or 4 weeks later Maternally derived antibodies can negatively influence the immune response to vaccination. In such cases where maternally derived antibodies are expected, a third injection may be appropriate from 15 weeks of age. Revaccination: Following a first booster vaccination one year after the primary vaccination course, subsequent vaccinations can be performed at intervals of three years for the leukaemia component. In this case, since annual revaccination is required for calcivirus, rhinotracheitis virus and panleucopenia virus components, a single dose of Feligen RCP can be used annually. This vaccine can be used as a booster for kittens or cats previously vaccinated with FELIGEN RCP and LEUCOGEN separately.

Leucogen FeLV - 1ml x10

137284
For the active immunisation of healthy unexposed cats from eight weeks of age against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease. Onset of immunity is three weeks after primary vaccination. The duration of immunity is one year after the primary vaccination. Following a first booster vaccination one year after the primary vaccination course, a duration of immunity of 3 years has been demonstrated. Primary course vaccination In cats of eight weeks and over, administer two doses of Leucogen 3 to 4 weeks apart. To protect kittens, the vaccination of female cats prior to mating is recommended. Maternally derived antibodies can negatively influence the immune response to vaccination. In such cases where maternally derived antibodies are expected, a third injection may be appropriate from 15 weeks of age. Revaccination Following a first booster vaccination one year after the primary vaccination course, subsequent vaccination can be performed at intervals of three years.

Nobi-Vac Dhppi - 1ml x10

120230
A live vaccine against canine distemper, infectious canine hepatits, canine parvovirus and canine parainfluenza virus infection for use in dogs. For active immunisation of dogs against canine distemper, canine hepatitis, canine parvovirus with a three year minimum duration of immunity and canine parainfluenza virus with a one year duration of immunity. However, the company recommends that the first year annual booster should be a ‘full’ DHPPi and Lepto vaccination. Nobivac DHPPi contains live, attenuated, freeze dried canine distemper virus, canine adenovirus-2 (CAV2), canine parvovirus and canine parainfluenza virus. The vaccine contains attenuated antigens to stimulate active immunity in dogs against canine distemper virus, canine parvovirus, infectious canine hepatitis caused by canine adenovirus 1 and respiratory disease caused by canine adenovirus type 2 and canine parainfluenza virus.